dm+d

Unassigned

New Medicines

Chronic pruritus associated with prurigo nodularis

Information

New molecular entity
Menlo Therapeutics
Menlo Therapeutics

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Apr 20In the light of non-significant results in PIII trials Menlo do not intend to further pursue serlopitant at this time [6].

Category

Neurokinin-1 (NK-1) receptor antagonist
Chronic pruritus is common, and can lead to seriously impaired quality of life; it may be associated with many diseases both local and systemic and there are few specific and effective treatments [1].
Chronic pruritus associated with prurigo nodularis
Oral

Trial or other data

Apr 20Studies MTI-105 and Study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis [6].